Hebron, Palestine
Hebron, Palestine

Hebron University is an independent Palestinian institution of higher education, with over 8,600 students, around 75% of whom are female. Wikipedia.


Time filter

Source Type

Soria J.-C.,University Paris - Sud | Felip E.,Hebron University | Cobo M.,Hospital Carlos Haya | Lu S.,Shanghai JiaoTong University | And 13 more authors.
The Lancet Oncology | Year: 2015

Background: There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung. Methods: We did this open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide. We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy. Participants were randomly assigned (1:1) to receive afatinib (40 mg per day) or erlotinib (150 mg per day) until disease progression. The randomisation was done centrally with an interactive voice or web-based response system and stratified by ethnic origin (eastern Asian vs non-eastern Asian). Clinicians and patients were not masked to treatment allocation. The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat population). The key secondary endpoint was overall survival. This trial is registered with ClinicalTrials.gov, NCT01523587. Findings: 795 eligible patients were randomly assigned (398 to afatinib, 397 to erlotinib). Median follow-up at the time of the primary analysis of progression-free survival was 6·7 months (IQR 3·1-10·2), at which point enrolment was not complete. Progression free-survival at the primary analysis was significantly longer with afatinib than with erlotinib (median 2·4 months [95% CI 1·9-2·9] vs 1·9 months [1·9-2·2]; hazard ratio [HR] 0·82 [95% CI 0·68-1·00], p=0·0427). At the time of the primary analysis of overall survival (median follow-up 18·4 months [IQR 13·8-22·4]), overall survival was significantly greater in the afatinib group than in the erloinib group (median 7·9 months [95% CI 7·2-8·7] vs 6·8 months [5·9-7·8]; HR 0·81 [95% CI 0·69-0·95], p=0·0077), as were progression-free survival (median 2·6 months [95% CI 2·0-2·9] vs 1·9 months [1·9-2·1]; HR 0·81 [95% CI 0·69-0·96], p=0·0103) and disease control (201 [51%] of 398 patients vs 157 [40%] of 397; p=0·0020). The proportion of patients with an objective response did not differ significantly between groups (22 [6%] vs 11 [3%]; p=0·0551). Tumour shrinkage occurred in 103 (26%) of 398 patients versus 90 (23%) of 397 patients. Adverse event profiles were similar in each group: 224 (57%) of 392 patients in the afatinib group versus 227 (57%) of 395 in the erlotinib group had grade 3 or higher adverse events. We recorded higher incidences of treatment-related grade 3 diarrhoea with afatinib (39 [10%] vs nine [2%]), of grade 3 stomatitis with afatinib (16 [4%] vs none), and of grade 3 rash or acne with erlotinib (23 [6%] vs 41 [10%]). Interpretation: The significant improvements in progression-free survival and overall survival with afatinib compared with erlotinib, along with a manageable safety profile and the convenience of oral administration suggest that afatinib could be an additional option for the treatment of patients with squamous cell carcinoma of the lung. Funding: Boehringer Ingelheim. © 2015 Elsevier Ltd.


News Article | December 1, 2016
Site: www.eurekalert.org

Researchers of the Sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, have first described the methylation profile of Ewing's sarcoma (ES), a cancer of bone and soft tissues that mainly affects children and teenagers. Their analysis has unveiled the potential of the PTRF gene as a prognostic marker of the disease and as a possible future therapeutic target in conjunction with the new genomic editing tools available. "This is the first time that the methylation profile of Ewing's sarcoma has been described," explains Dr. Òscar Martínez-Tirado, lead author of the study. DNA methylation is a type of epigenetic modification capable of controlling gene expression, that is, it can activate or deactivate genes that enhance to or block characteristics and processes in individuals, including the development of tumors. Using bioinformatic tools, the research team looked for common elements that allowed them to relate the set of differentially hypomethylated or hypermethylated genes they found in the tumor samples. The researchers identified a group of 12 genes related to the structure of the cell membrane; Among them, the precursor of the protein PTRF particularly called their attention by its relation with the caveolae, small invaginations that are present in the membrane of some cells; the IDIBELL group has extensive experience in the study of these structures and their relationship with ES. The team correlated the presence of PTRF in samples from 67 patients. "Initially, we saw that those patients who express PTRF have a better survival, therefore, we could consider this protein as a potential marker of prognosis of the disease," concludes Martinez-Tirado. Normal cells with caveolae express both the PTRF protein and caveolin-1 (CAV1), another protein related to caveolae formation. In contrast, tumor cells in ES do not have caveolae, nor express PTRF. "This made us think about the possibility of exogenously reintroducing the precursor gene PTRF into the study cell lines", explains the researcher. "In those that also expressed CAV1, the reintroduction of PTRF triggered caveolae formation. For tumor cells, this modification of the structure is so stressful that it destroys them". In addition, researchers have shown that the formation of the caveolae in these cells activates a known cell death signaling pathway promoted by the p53 protein. Current epigenetic drugs are rather nonspecific, but new CRISPR genomic editing tools have the potential to be used to demethylate specific genes from a tumor cell in the future. "If we are able to specifically act on the PTRF promoter gene so that the protein is expressed at normal levels, we would induce cell death and therefore we would have a promising new personalized therapeutic option for ES." This has been a highly collaborative work, both at the research level, as researchers by two groups from IDIBELL's epigenetics and cancer biology program, Germans Trias Institute, Institute of biomedicine of Seville, University Hospital la Paz, Children's University Hospital Niño Jesús, San Juan de Dios Hospital, Vall d'Hebron University Hospital and Virgen del Rocío University Hospital have collaborated, as well as at a financial level level, given that the project is funded by the Carlos III Health Institute, the AECC and the Alba Pérez Foundation.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from three Phase III studies of its investigational medicine OCREVUS™ (ocrelizumab) – the OPERA I and OPERA II studies in relapsing multiple sclerosis (RMS) and the ORATORIO study in primary progressive multiple sclerosis (PPMS) – were published in the December 21, 2016 online issue of the New England Journal of Medicine (NEJM). Data from the OCREVUS Phase III studies showed consistent and clinically meaningful reductions in major markers of disease activity and progression compared with Rebif® (interferon beta-1a) in RMS and with placebo in PPMS. The primary endpoint was met in all three studies, which includes relative reduction of annualized relapse rate in the RMS studies and relative reduction in the progression of clinical disability sustained for at least 12 weeks in the PPMS study. Key secondary endpoints in all three studies were also met, including multiple measures of disability progression and brain lesion activity. “These publications that indicate that B cells play a central role in MS are the result of a longstanding collaboration between the scientific community and industry for the benefit of people with MS,” said Stephen Hauser, M.D., Chair of the Scientific Steering Committee of the OPERA studies, Director of the Weill Institute for Neurosciences and Chair of the Department of Neurology at the University of California, San Francisco. “In the OPERA I and OPERA II RMS studies, OCREVUS consistently and significantly reduced disease activity and disability progression compared with a standard-of-care high-dose interferon while demonstrating a favorable safety profile. The consistency of these pioneering data, the effect seen in these clinical studies and the favorable safety profile may support treating MS earlier with a high-efficacy disease-modifying medicine.” Data from two identical studies (OPERA I and OPERA II) in RMS showed OCREVUS was superior to high-dose Rebif (interferon beta-1a), a well-established MS therapy, in reducing three major markers of disease activity: relapses (primary endpoint), disability progression and brain lesion activity over the two-year controlled treatment period. In a separate PPMS study (ORATORIO), OCREVUS significantly reduced the risk of confirmed disability progression sustained for at least 12 weeks (primary endpoint) and 24 weeks (a key secondary endpoint) compared with placebo. OCREVUS treatment was also superior to placebo on other key measures of disease progression in PPMS patients including the time required to walk 25 feet, the volume of chronic brain lesions and brain volume loss. “OCREVUS is the first and only investigational medicine to significantly reduce the progression of physical disability in primary progressive MS in a large Phase III study,” said Xavier Montalban, M.D., Ph.D., Chair of the Scientific Steering Committee of the ORATORIO study and Professor of Neurology and Neuroimmunology at Vall d’Hebron University Hospital, Research Institute and Cemcat, Barcelona, Spain. “Over the last decade, other molecules have tried and failed to demonstrate efficacy for PPMS, so the positive results for OCREVUS mark an important step in our understanding of this highly disabling form of the disease.” The OCREVUS safety profile was evaluated in the three Phase III studies. In the RMS studies, the proportion of patients with serious adverse events and serious infections was similar between the OCREVUS and interferon beta-1a treatment groups. In the PPMS study, the proportion of patients with adverse events and serious adverse events was similar between the OCREVUS and placebo treatment groups. Safety analyses continue in the open-label extension studies in both RMS and PPMS. Marketing applications for OCREVUS, submitted for RMS and PPMS, have been accepted and are currently under review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). As previously announced, OCREVUS was granted Priority Review Designation by the FDA with a targeted action date of March 28, 2017. OCREVUS™ is the proprietary name submitted to the FDA for the investigational medicine ocrelizumab. About the OPERA I and OPERA II studies in RMS OPERA I and OPERA II are Phase III, randomized, double-blind, double-dummy, global multi-center studies evaluating the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months) compared with interferon beta-1a (44 mcg administered by subcutaneous injection three times per week) in 1,656 people with relapsing forms of MS. In these studies, relapsing MS (RMS) was defined as relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) with relapses. The primary and key secondary endpoints were previously presented at the 2015 congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Data from the Phase III OPERA studies in patients with RMS showed: As previously reported at the 2016 American Academy of Neurology Annual Meeting (AAN), OCREVUS increased the proportion of patients who achieved no evidence of disease activity (NEDA) by 64 percent and 89 percent compared with interferon beta-1a at 96 weeks in OPERA I and OPERA II, respectively (p<0.001 and p<0.001). The exploratory endpoint is based on a combination of three major markers of disease activity (relapses, disability progression and inflammatory and chronic MRI activity) and provides a more comprehensive measurement of disease activity and the effect of treatment than any single endpoint. Overall, the proportion of patients in the OCREVUS group with adverse events was similar to interferon beta-1a in both studies (80.1 percent in the OCREVUS group vs. 80.9 percent in the interferon beta-1a group in OPERA I and 86.3 percent in the OCREVUS group vs. 85.6 percent in the interferon beta-1a group in OPERA II); the most common adverse event associated with OCREVUS was infusion-related reactions (34.3 percent of patients who received OCREVUS experienced at least one infusion-related reaction vs. 9.9 percent for interferon beta-1a). The proportion of patients in the OCREVUS group with serious adverse events, including serious infections, was also similar to interferon beta-1a (6.9 percent in the OCREVUS group vs. 7.8 percent in the interferon beta-1a group in OPERA I and 7.0 percent in the OCREVUS group vs. 9.6 percent in the interferon beta-1a group in OPERA II). About the ORATORIO study in PPMS ORATORIO is a Phase III, randomized, double-blind, global multi-center study evaluating the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months; given as two 300 mg infusions two weeks apart) compared with placebo in 732 people with PPMS. In contrast to the OPERA I and OPERA II studies, where the blinded treatment period was two years, the blinded treatment period of the ORATORIO study continued beyond that until all patients had received at least 120 weeks of either OCREVUS or placebo and a predefined number of confirmed disability progression (CDP) events was reached overall in the study. The primary and key secondary endpoints were previously presented at the 2015 congress of ECTRIMS. Data from the Phase III ORATORIO study in patients with PPMS showed: Overall, the proportion of patients in the OCREVUS group with adverse events was similar to placebo (95.1 percent vs. 90.0 percent, respectively); the most common adverse event associated with OCREVUS was infusion-related reactions (39.9 percent vs. 25.5 percent for placebo). The proportion of patients in the OCREVUS group with serious adverse events, including serious infections, was also similar to placebo (20.4 percent vs. 22.2 percent, respectively). OCREVUS is an investigational, humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, and therefore important functions of the immune system may be preserved. Multiple sclerosis (MS) is a chronic disease that affects an estimated 400,000 people in the U.S., for which there is currently no cure. MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the brain, spinal cord and optic nerves, causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults. Approximately 95 percent of people with MS have a relapsing form or primary progressive MS at diagnosis. Relapsing-remitting MS (RRMS) is the most common form of the disease and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. Over time, some people with RRMS experience steadily worsening symptoms and transition to secondary progressive MS (SPMS), with or without relapses. Disease activity and progression can occur even when people do not show signs or symptoms of MS, despite available relapsing MS treatments. Primary progressive MS (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 10-15 percent of people with MS are diagnosed with the primary progressive form of the disease. There are no approved treatments for PPMS. Neuroscience is a major focus of research and development at Genentech and Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases. Roche has more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease and autism. Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. All trademarks used or mentioned in this release are protected by law. Rebif is a registered trademark of Merck KGaA and EMD Serono, Inc.


News Article | December 19, 2016
Site: www.eurekalert.org

Mosaic Biomedicals SL today announced a merger with Northern Biologics Inc. that will enable the accelerated development of MSC-1, a humanized antibody expected to begin clinical trials across several tumor types in 2017, with multiple sites planned throughout Europe and North America. MSC-1 is a first-in-class antibody that targets LIF, a pleiotropic cytokine that is overexpressed in certain solid tumors. LIF promotes cancer progression by regulating the tumor microenvironment as well as inducing self-renewal in tumor-initiating cells. Pioneering work on the role of LIF in oncogenesis, and the discovery of MSC-1, was performed under the leadership of Joan Seoane, Ph.D., a co-founder of Mosaic and Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO). Versant Ventures has expanded its series A commitment to the company and Celgene Corp. has exercised an option to acquire certain rights to the MSC-1 program under its existing agreement with Northern Biologics. Following the transactions, full funding is in place for the early clinical development of MSC-1, in addition to a preclinical portfolio of therapeutic antibodies. Dr. Seoane, who has joined the Board of Directors of the merged company, observes: "This merger is a fantastic way for the Mosaic Biomedicals team to join forces with Northern and bring together the capital, know-how, talent, and international leadership required to develop the most effective therapeutic antibodies as quickly as possible." "With the support of key partners and the financial strength to give MSC-1 the highest chance of success, this agreement represents unparalleled opportunity for Mosaic to reach its full potential," added Dr. Judit Anido, co-founder of Mosaic and member of the Executive Team. Dr. José Baselga, also a Mosaic co-founder, will serve as Chair and Senior Medical Advisor on the Scientific Advisory Board of the newly merged company. Mosaic was established by Dr. Seoane at VHIO, a comprehensive cancer center set within the privileged location of the Vall d´Hebron University Hospital. VHIO researchers and physician-scientists adopt a purely translational research model, working as multidisciplinary teams to accelerate and advance personalized and targeted therapies against cancer. Mosaic is VHIO's first spinout company, set up in partnership with ICREA and the Vall d'Hebron Research Institute (VHIR). Public funding received from the Retos de Colaboración program, ENISA, CDTI and ERC´s PoC, among others, have been essential in fueling Mosaic's creation, aimed at rapidly translating scientific discovery into benefits at the patient level. The company will also become an economic engine returning value to the very society that has invested in cancer research" say Dr. Seoane and Dr. Anido, who also gratefully acknowledged the support received from the first Business Angels and friends who believed in the project from the outset and provided funding for the initial set-up steps. Subsequent investment from Versant and Caixa Capital Risc, spurred further development of Mosaic Biomedicals and drove MSC-1 to the verge of clinical trials. The merger with Northern Biologics and significant new investment has further raised the team's ambitions and will bring the project to an exciting new stage in clinical development. "None of this would have been possible without outstanding teamwork -- from within my research group in particular, working daily on what really matters, namely, pushing the boundaries in cancer science. This tremendous undertaking, now supported by optimal financial and technical conditions, will allow us to continue to progress and ultimately improve the treatment and care of an increasing number of patients with cancer," said Dr. Seoane. Mosaic Biomedicals is a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor's immune system. Mosaic is a spin-off of the Vall d'Hebron Institute of Oncology, Institució Catalana de Recerca i Estudis Avançats (ICREA) and the Vall d'Hebron Institute of Research (VHIR), backed by Versant Ventures, Caixa Capital Risc and several angel investors. Northern Biologics was launched in June 2014 by Blueline Bioscience, a Canadian biotechnology incubator backed by venture capital firm Versant Ventures, in partnership with the University of Toronto and University Health Network's Princess Margaret Cancer Centre. Headquartered in the MaRS Discovery District of Toronto, the company is developing a portfolio of antibody-based therapeutics for oncology and fibrosis.


Martinez P.,Hebron University | Sales Fidalgo P.A.,Instituto Portugues Of Oncologia Of Coimbra | Felip E.,Hebron University
Expert Opinion on Investigational Drugs | Year: 2014

Introduction: Small-cell lung cancer (SCLC) accounts for 15-20% of all lung cancer cases with few advances made in the systemic treatment and outcomes for extensive-stage SCLC. Many strategies have been evaluated over the past 15 years but none of these approaches has resulted in improved survival rates for patients with SCLC. The IGF receptor (IGF-R) pathway represents a potential actionable target in SCLC patients. Indeed, the IGF-R pathway is involved in cancer development and progression and regulates different vital processes including fetal development, growth and metabolism.


Thabayneh K.M.,Hebron University
Radiation protection dosimetry | Year: 2013

The activity concentrations of naturally occurring radioactive materials such as (226)Ra, (238)U, (232)Th, (40)K and (137)Cs were measured for 44 plant samples collected from different locations in the northwestern region of the West Bank, Palestine, using high-resolution gamma ray spectroscopy. The activity concentrations of radionuclides in the investigated plant samples ranged from 7.5 to 157.6 Bq kg(-1) for (226)Ra, 7.5 to 66.1 Bq kg(-1) for (238)U, 1.8 to 48.5 Bq kg(-1) for (232)Th, 14.3 to 1622 Bq kg(-1) for (40)K and <0.1 to 4.7 Bq kg(-1) for (137)Cs. The average values of these activities were 48.3, 26.5, 10.1, 288.0 and 2.2 Bq kg(-1), for (226)Ra, (238)U, (232)Th, (40)K and (137)Cs, respectively. The study presents the total gamma radiation dose rate assessed from natural radionuclides,(137)Cs and cosmic radiation, the dose rate of each radionuclide and the effective dose for all the samples. The radiological health implication to the population that may result from these doses is found to be low, except in few cases. The measurements have been taken as representing a baseline database of values of these radionuclides in the plants in the area.


Gattarello S.,Hebron University
Current Infectious Disease Reports | Year: 2015

Despite all published literature, controversies remain about the optimal antibiotic treatment in community-acquired pneumonia. The most debated issue is whether it is necessary to empirically start one or two antibiotics, i.e. whether or not to cover atypical agents. A review of the literature published from 2005 to present was completed, searching for new insights in antibiotic treatment in community-acquired pneumonia (CAP) focusing on monotherapy versus combined therapy. Forty-one articles were identified enrolling outpatients, and patients admitted to the ward and to the intensive care unit: 11 were meta-analyses, 8 clinical trials and 22 observational—prospective and retrospective—studies. Although controversies remain in the treatment of CAP, the use of combination therapy seems to be associated with a lower mortality in case of severe CAP that requires intensive care unit (ICU) admission, especially when a beta-lactam–macrolide association is delivered. Moreover, combination therapy is associated with better outcomes—although not always with a lower mortality—in cases of non-ICU patients with risk factors for a poor outcome, bacteraemic pneumococcal pneumonia and high suspicion of infection by atypical agents. In this setting, it appears that the best choice of treatment may be a beta-lactam–macrolide regimen. © 2015, Springer Science+Business Media New York.


Mohammad A.G.,Hebron University | Adam M.A.,Hebron University
Catena | Year: 2010

The effects of different vegetation types on runoff generation and soil erosion were investigated. The study was conducted at the Southern part of West Bank, about 10 Km north-west of Hebron city, during 2005, 2006 and 2007. Five treatments were implemented; forests planted with P. halepensis (F), natural vegetation dominated by S. spinosum (W.S), natural vegetation where S. spinosum was removed (W/o.S), cultivated land (C), and deforestation (Df). Three types of data were estimated in each plot: runoff after each rainfall event, sedimentation at the end of the rainy season, and chemical and physical soil properties. The obtained results indicate that there are significant and important differences in runoff generation and sediment production with respect to the different types of vegetative cover. Forest and natural vegetation dominated by S. spinosum treatments exhibited the lowest amounts of runoff, with averages of 2.02 and 1.08 mm, respectively, in comparison to other treatments. The removal of S. spinosum significantly increased the total amount of runoff and sedimentation compared to the forest and S. spinosum treatments. In addition, runoff significantly increased (4.03 mm) for the Df treatment compared to that of the forest site. The greatest amount of sedimentation was observed in cultivated land and with deforestation. The forest and S. spinosum treatments exhibited the highest percentages of organic matter of the five investigated treatments. The results indicate that forests and natural vegetation dominated by S. spinosum prevent or decrease the risk of runoff and soil erosion. In conclusion, the removal of S. spinosum and forest trees as a means to improve rangeland productivity increases runoff and sediment fluxes if not accompanied by careful grazing management. In addition, interchangeably using arid and semi-arid lands as rangeland and for cultivation may have significant negative impacts on the production potential of these lands. © 2010 Elsevier B.V. All rights reserved.


Aqra F.,Hebron University | Ayyad A.,Hebron University
Materials Letters | Year: 2011

A calculation, based on statistical thermodynamics, of the surface tension of pure liquid gold, in the temperature range 1337-1653 K, is described. The calculated surface tension of liquid gold was found to be 1100 mJ/m2 that agrees well with the reported experimental value (1149 mJ/m2). Results reveal that below 1480 K, the surface excess entropy changes by one order of magnitude (0.0151 mJ/m2 K) as compared to the value above this temperature (0.1773 mJ/m2 K), and thus predicting a structural changes at the surface of pure molten gold at high temperature. © 2011 Elsevier B.V. All rights reserved.


Radon concentration and annual effective doses were measured in drinking water in the Southern Part of West Bank - Palestine, by using both passive and active techniques. 184 samples were collected from various sources i.e. tap water, groundwater, rain waters and mineral waters. It is found that the annual effective dose resulting from inhalation and ingestion of radon emanated from all types of drinking water is negligible compared to the total annual effective dose from indoor radon in the region. Results reveal that there is no significant public health risk from radon ingested and inhalation with drinking water in the study region. •The radon concentrations are measured for drinking water samples in the southern part of West Bank - Palestine.•We conclude that there is no significant public health risk from radon ingested and inhalation with drinking water in the study region. © 2015 Published by Elsevier Ltd.

Loading Hebron University collaborators
Loading Hebron University collaborators